

Multimorbidity patterns influence mobility disability prevention in frail older adults from the SPRINTT trial

Received: 25 September 2025

Accepted: 13 July 2026

Published online: 31 August 2026

 Check for updates

A list of authors and their affiliations appears at the end of the paper

Preserving independence in older adults is a public health priority. Lifestyle interventions can prevent physical disability, but whether their efficacy is influenced by multimorbidity profiles is unclear. In this post hoc analysis of the SPRINTT randomized trial ([NCT02582138](#)), we investigated whether the efficacy of a multicomponent intervention (physical activity with technological support and nutritional counseling) differed across multimorbidity patterns. We included 1,199 community-dwelling adults aged ≥ 70 years with frailty, sarcopenia and two or more chronic conditions. Latent class analysis identified four multimorbidity patterns: unspecific (55%), psychiatric (24%), cardiometabolic (13%) and respiratory (7%). The intervention reduced the overall risk of mobility disability or death (hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.66–0.92). In subgroup analyses, a significant benefit was observed in participants with a psychiatric multimorbidity pattern (HR 0.65, 95% CI 0.47–0.92). Bayesian partial pooling analyses also supported a beneficial effect in the unspecific pattern (HR 0.80, 95% credible interval 0.69–0.93), while estimates for the cardiometabolic and respiratory patterns were imprecise and not statistically significant. The intervention increased the event-free probability at 24 and 36 months and extended the time free from mobility disability or death by 2.09 months overall. Gains were 3.09 months in the psychiatric pattern and 1.99 months in the unspecific pattern, with no meaningful differences observed in the cardiometabolic and respiratory patterns. These findings suggest that the composition of multimorbidity may influence responsiveness to lifestyle interventions and that stratification based on disease patterns could improve the targeting and effectiveness of preventive strategies in older adults.

Globally, the population of older adults is expanding at an unprecedented pace, with those aged 65 years and older representing the fastest-growing demographic group in Europe¹. While increased longevity is a major public health achievement, a key priority is to ensure that these additional years are spent in good health, preserving functional capacity, independence and quality of life². Preventing functional decline and disability has, therefore, become a central public health objective².

Mobility, defined as the ability to walk independently, is a cornerstone of autonomy in later life^{3,4}. Loss of mobility is associated with morbidity, disability and mortality⁵. Operationally, the capacity to walk 400 m is recognized as a valid proxy for community ambulation and a critical prerequisite for maintaining independence^{6,7}. Evidence suggests that lifestyle-based interventions can slow or even reverse the progression toward mobility disability in older adults with functional limitations. The Lifestyle Interventions and Independence

✉ e-mail: emanuele.marzetti@unicatt.it




Fig. 1 | Flowchart of the SPRINTT multimorbidity post hoc analysis. Of the 1,519 randomized participants in the SPRINTT trial, 1,199 with an SPPB score of 3–7 (the primary trial population) and at least two chronic diseases were included in the present post hoc analysis. DXA, dual-energy X-ray absorptiometry.

for Elders (LIFE) randomized trial demonstrated that a structured, moderate-intensity physical activity program significantly reduced the incidence of mobility disability over 2.6 years in physically inactive older adults at risk for disability, compared to health education⁸. Similarly, the Sarcopenia and Physical Frailty IN older people: multi-component Treatment strategies (SPRINTT) randomized trial showed that a multicomponent intervention, comprising physical activity with technological support and nutritional counseling, reduced the risk of mobility disability in older adults with physical frailty and sarcopenia, relative to a health education program⁹. Neither trial detected significant heterogeneity in intervention effects across individual disease conditions.

Multimorbidity, typically defined as the co-occurrence of two or more chronic conditions, is highly prevalent in older individuals¹⁰. Diseases do not codevelop randomly; rather, they tend to cluster within

individuals due to shared risk factors, common pathophysiological mechanisms or iatrogenic effects of treatments¹⁰. Distinct multimorbidity patterns, such as cardiometabolic, neuropsychiatric and musculoskeletal, have been identified, each carrying different implications for functional decline, dementia, disability, institutionalization and survival^{11–15}. Hence, these patterns delineate relatively homogeneous subgroups with shared biology and clinical trajectories.

Although the impact of multimorbidity patterns on responsiveness to lifestyle interventions is not well established, preliminary evidence suggests that efficacy may differ across multimorbidity profiles. For example, secondary analyses of exercise trials in community-dwelling and hospitalized frail older adults reported that functional benefits varied by disease pattern^{16,17}. Given the heterogeneity inherent in multimorbidity, stratifying individuals according to disease patterns may improve the targeting and effectiveness

Table 1 | Description of study population overall and by intervention group

Characteristics	Overall (n=1,199) ^a	Healthy aging lifestyle education program (n=598) ^a	Multicomponent intervention (n=601) ^a	P value ^b
Sex				0.8
Female	855 (71%)	424 (71%)	431 (72%)	
Male	344 (29%)	174 (29%)	170 (28%)	
Age (years)	79.0 (75.0–84.0)	79.0 (75.0–83.0)	79.0 (75.0–84.0)	0.7
Age group				0.6
70–74	283 (24%)	138 (23%)	145 (24%)	
75–79	367 (31%)	196 (33%)	171 (28%)	
80–84	293 (24%)	138 (23%)	155 (26%)	
85–89	196 (16%)	96 (16%)	100 (17%)	
≥90	60 (5.0%)	30 (5.0%)	30 (5.0%)	
Number of chronic conditions	6.00 (5.00–8.00)	6.00 (5.00–8.00)	6.00 (5.00–8.00)	0.4
Multimorbidity pattern				0.9
Unspecific	660 (55%)	330 (55%)	330 (55%)	
Respiratory	88 (7.3%)	40 (6.7%)	48 (8.0%)	
Psychiatric	290 (24%)	147 (25%)	143 (24%)	
Cardiometabolic	161 (13%)	81 (14%)	80 (13%)	

^aData are presented as n (%) or median (IQR). ^bP values were calculated using Pearson’s chi-squared test or the Wilcoxon rank-sum test.

of preventive interventions. Using data from the SPRINTT trial, we investigated whether multimorbidity patterns modified responses to a multicomponent lifestyle intervention and whether disease clustering influenced intervention responsiveness in frail, sarcopenic older adults with multimorbidity.

Results

Participants

Of the 1,205 randomized participants with baseline scores on the Short Physical Performance Battery (SPPB)¹⁸ of 3–7 (the primary trial population), 1,199 with multimorbidity (defined as two or more chronic conditions) were included in this analysis (Fig. 1). The median age was 79.0 years (interquartile range (IQR) 75.0–84.0), and 71% were women. The median number of chronic conditions was 6.0 (IQR 5.0–8.0). Baseline characteristics were comparable between the intervention groups (Table 1).

Multimorbidity patterns

We identified four multimorbidity patterns through latent class analysis (LCA) (Supplementary Fig. 1): unspecific (no overexpressed diseases; 660 participants, 55%), respiratory (88 participants, 7%), psychiatric (290 participants, 24%) and cardiometabolic (161 participants, 13%). Overexpressed diseases across identified multimorbidity patterns are shown in a bubble plot in Fig. 2, while their prevalence and distribution are reported in Supplementary Table 2. Multimorbidity patterns were evenly distributed between the intervention groups ($P = 0.9$).

Significant differences were observed across multimorbidity patterns in sex, age and disease burden (Table 2). Those in the psychiatric group were predominantly women (89%), whereas the cardiometabolic group included more men (57%) and had the highest median age (82 years; IQR 77–86). Participants in the unspecific group had the lowest disease burden (median 5 conditions; IQR 4–6), while the cardiometabolic group had the highest disease burden (median 9 conditions; IQR 7–10). Cumulative incidence of mobility disability or death differed significantly across patterns (Fig. 3; $P = 0.007$), with higher event rates in the cardiometabolic ($P = 0.04$; 178 events per person-year) and psychiatric ($P = 0.001$; 130 events per person-year) groups compared

to the unspecific group (105 events per person-year). The respiratory pattern (137 events per person-year) showed a similar event rate to the psychiatric pattern.

Inverse probability of treatment weighting

Inverse probability of treatment weighting (IPTW) was applied to ensure balance between treatment arms within each multimorbidity pattern using all baseline covariates listed in Table 2. As shown in Supplementary Fig. 2, all patterns exhibited some degree of initial imbalance; however, IPTW substantially improved balance across covariates. After weighting, covariate balance improved substantially across multimorbidity patterns, with most absolute standardized differences reduced to <0.1 and nearly all <0.2 , indicating acceptable balance for the weighted analyses.

Efficacy endpoints

After adjustment for multimorbidity patterns, participants in the multicomponent intervention group had a significantly lower risk of mobility disability than those in the health education group (hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.66–0.92). Statistical interaction between the intervention and the multimorbidity patterns was not significant ($P = 0.870$). Nevertheless, based on the high biological plausibility of effect modification by multimorbidity patterns on the intervention, we performed subgroup analyses according to these patterns. These analyses were carried out using two different approaches: a classic frequentist approach and a recently proposed Bayesian method to estimate subgroup effects from intervention studies¹⁹. In accordance with the frequentist approach, the only statistically significant reduction in mobility disability was observed among participants displaying a psychiatric pattern (HR 0.65, 95% CI 0.47–0.92; Fig. 4a and Supplementary Fig. 3). The Bayesian partial pooling analysis yielded broadly consistent findings, with posterior HRs indicating a protective effect of the intervention in the unspecific (HR 0.80, 95% credible interval (CrI) 0.69–0.93) and psychiatric (HR 0.76, 95% CrI 0.60–0.91) multimorbidity patterns, while the respiratory and cardiometabolic patterns showed more heterogeneous and less precise estimates (Fig. 4b). The posterior probability that the intervention is beneficial (HR <1) was 0.998 for the unspecific pattern, 0.998 for the




Fig. 2 | Bubble plot depicting the prevalence of chronic diseases in each of the multimorbidity patterns. Red bubbles indicate diseases considered overexpressed within each multimorbidity pattern (unspecific, $n = 660$; respiratory, $n = 88$; psychiatric, $n = 290$; cardiometabolic, $n = 161$). Overexpression is defined by an observed-to-expected ratio of 2 or greater and an exclusivity of at least 25%, indicating that the disease is both disproportionately prevalent and relatively unique to that pattern. CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal.

Table 2 | Description of study population overall and by multimorbidity pattern

Characteristics	Overall ($n=1,199$) ^a	Unspecific ($n=660$) ^a	Respiratory ($n=88$) ^a	Psychiatric ($n=290$) ^a	Cardiometabolic ($n=161$) ^a	P value ^b
Sex						<0.001
Female	855 (71%)	460 (70%)	67 (76%)	259 (89%)	69 (43%)	
Male	344 (29%)	200 (30%)	21 (24%)	31 (11%)	92 (57%)	
Age (years)	79.0 (75.0–84.0)	79.0 (74.8–83.0)	78.0 (74.0–81.0)	78.0 (74.0–83.0)	82.0 (77.0–86.0)	<0.001
Age group						<0.001
70–74	283 (24%)	165 (25%)	23 (26%)	74 (26%)	21 (13%)	
75–79	367 (31%)	189 (29%)	37 (42%)	99 (34%)	42 (26%)	
80–84	293 (24%)	178 (27%)	12 (14%)	64 (22%)	39 (24%)	
85–89	196 (16%)	100 (15%)	15 (17%)	39 (13%)	42 (26%)	
≥90	60 (5.0%)	28 (4.2%)	1 (1.1%)	14 (4.8%)	17 (11%)	
Number of chronic diseases	6.00 (5.00–8.00)	5.00 (4.00–6.00)	8.00 (7.00–10.00)	7.00 (5.25–8.00)	9.00 (7.00–10.00)	<0.001
Number of drugs	5 (3–7)	4 (3–6)	6 (4–9)	5 (3–7)	8 (6–10)	<0.001
SPPB score	7.00 (6.00–7.00)	7.00 (6.00–7.00)	6.00 (5.00–7.00)	7.00 (6.00–7.00)	6.00 (5.00–7.00)	0.021
MMSE score	28.00 (27.00–29.00)	28.00 (27.00–29.00)	28.00 (26.00–29.00)	28.00 (27.00–29.00)	28.00 (26.00–29.00)	0.023
Current smoking	68 (5.8%)	40 (6%)	7 (8.0%)	18 (6.2%)	3 (1.9%)	0.20
Missing	19	14	0	0	5	
Drinking alcohol in the last 12 months	441 (40%)	238 (40%)	30 (37%)	102 (38%)	71 (48%)	0.2
Missing	97	61	6	18	12	
Living alone	595 (50%)	325 (50%)	42 (48%)	162 (56%)	66 (42%)	0.044
Missing	17	13	0	0	4	
Low education (none or elementary)	285 (25%)	165 (26%)	23 (27%)	65 (23%)	32 (21%)	0.6
Missing	47	23	2	11	11	
Manual occupation	323 (30%)	173 (28%)	37 (45%)	76 (30%)	37 (25%)	0.010
Missing	112	52	6	40	14	

^aData are presented as n (%), median (IQR) and counts of missing values. ^bP values were calculated using Pearson’s chi-squared test or the Kruskal–Wallis rank-sum test.




Fig. 3 | Kaplan–Meier incidence curves for the primary endpoint stratified by multimorbidity patterns. The incidence curves differed significantly across multimorbidity patterns ($P < 0.001$, two-sided log-rank test), rejecting the null hypothesis that the probability of incident mobility disability or death was identical across all groups.

psychiatric pattern, 0.851 for the cardiometabolic pattern and 0.736 for the respiratory pattern, further supporting strong evidence of benefit in the unspecific and psychiatric groups and more uncertain evidence in the remaining patterns.

At 24 months, the event-free probability was 7.5% higher in the multicomponent intervention group than in the health education group (absolute difference 0.075, 95% CI 0.03–0.12), increasing to 8.2% at 36 months (absolute difference 0.082, 95% CI 0.033–0.131). At 12 months, the corresponding absolute difference was 5.3% (0.053, 95% CI 0.01–0.10). Over 36 months, participants assigned to the multicomponent intervention remained free from mobility disability or death for an average of 2.09 months longer (95% CI 0.86–3.33 months) than those in the health education group.

When analyzed by multimorbidity pattern, consistent benefits of the intervention were observed among participants with the unspecific pattern, with absolute increases in event-free probability of 4.7% at 12 months (0.047, 95% CI 0.007–0.086), 6.8% at 24 months (0.068, 95% CI 0.025–0.112) and 8.1% at 36 months (0.081, 95% CI 0.029–0.133). These gains translated into 1.90 additional event-free months over 36 months (95% CI 0.73–3.07 months). A larger effect was seen in the psychiatric pattern, where absolute differences reached 8.8% at 12 months (0.088, 95% CI 0.016–0.159), 12.2% at 24 months (0.122, 95% CI 0.036–0.208) and 13.1% at 36 months (0.131, 95% CI 0.031–0.231). Participants in this group remained event-free for 3.45 months longer over 36 months (95% CI 1.14–5.77 months). In contrast, no meaningful benefit was observed for the respiratory and cardiometabolic patterns,

for which the absolute differences at 12, 24 and 36 months were close to zero and not statistically significant (Fig. 5).

In the simulation analysis, the power to detect a treatment-by-pattern interaction increased steadily with sample size, surpassing 80% between 6,000 and 7,000 participants (Supplementary Fig. 4). Because the simulation assumptions were derived from the observed data structure and estimated interaction effects, these findings should be interpreted as contextual rather than confirmatory. Nevertheless, the results suggest that the SPRINTT sample ($n = 1,199$) may have had limited power to detect interaction effects of the magnitude observed in the present study through formal interaction testing or Bonferroni-corrected subgroup-specific analyses. The false-positive rate remained close to the nominal 5% level, as expected.

Discussion

In this post hoc analysis of the SPRINTT trial, we found that the efficacy of a multicomponent lifestyle intervention in preventing mobility disability among community-dwelling older adults with physical frailty and sarcopenia varied according to multimorbidity patterns. Participants with unspecific and psychiatric patterns of multimorbidity experienced 20% and 24% reductions, respectively, in the risk of the composite outcome, which included mobility disability and death. These participants also demonstrated higher event-free probabilities at 24 and 36 months, as well as 2 and 3.5 additional months free from mobility disability, compared to those with other multimorbidity patterns.




Fig. 4 | Hazard ratios (HRs) of the intervention effect with 95% confidence intervals (CIs, frequentist) and 95% credible intervals (CrIs, Bayesian) for the overall population ($n = 1199$) and each multimorbidity pattern (unspecific, $n = 660$; respiratory, $n = 88$; psychiatric, $n = 290$; cardiometabolic, $n = 161$). In both panels, the central point denotes the estimated HR, and the horizontal error bars represent the corresponding 95% CI (a) or 95% CrI (b). In a, HRs were

estimated from separate IPTW-adjusted Cox proportional hazards models stratified by sex and study site. In b, the corresponding estimates were derived from an IPTW-adjusted Bayesian partial pooling Cox model, which shrinks subgroup-specific estimates toward the overall effect based on the amount of information available within each multimorbidity pattern. HRs <1 indicate a protective effect of the intervention.




Fig. 5 | Absolute measures of effect in overall ($n = 1199$) and in subgroup analyses by multimorbidity patterns (unspecific $n = 660$; respiratory $n = 88$; psychiatric $n = 290$; cardiometabolic $n = 161$) with 95% confidence intervals (CIs). In all panels, the central point denotes the estimated absolute treatment effect, and the horizontal error bars represent the corresponding 95% CI. The

absolute differences between the two intervention groups in the event-free probability of the primary endpoint at 24 and 36 months, and in the 36-month restricted mean time free from mobility disability or death, together with the corresponding 95% CIs, were estimated using separate Royston–Parmar flexible parametric survival models in the overall population and within each pattern.

The LIFE⁸ and SPRINTT⁹ trials showed that an exercise-based intervention and a multicomponent lifestyle intervention, respectively, reduced incident mobility disability in vulnerable older adults, with no clear evidence of effect modification across conventional subgroups (for example, age, sex, ethnicity/race, presence of cardiovascular disease or diabetes, and baseline 4-m gait speed). Our analysis extends

these findings by demonstrating that disease clustering, rather than single conditions or broad demographic factors, may significantly modify responsiveness to intervention.

This interpretation aligns with prior studies. Martínez-Velilla et al.¹⁷ reported heterogeneous responses to an exercise intervention across multimorbidity profiles in hospitalized frail older adults. The metabolic

multimorbidity pattern, similar in composition to our unspecific multimorbidity pattern, showed the greatest gains in physical function and cognition, whereas the psychiatric pattern was associated with marked improvements in quality of life and depressive symptoms but only modest functional benefits¹⁷. Further supporting the concept of multimorbidity-driven effect modification, Corica et al.²⁰, in a secondary analysis of the Mobile Health (mHealth) Technology to Improve Care for Patients with Atrial Fibrillation (mAFA-II) cluster randomized trial, evaluated an integrated care pathway in patients with atrial fibrillation grouped as low morbidity, hypertension/coronary artery disease or mixed high morbidity. They observed substantial heterogeneity in intervention benefits, with patients in the milder multimorbidity groups achieving the greatest relative risk reduction in the composite outcome of all-cause death, stroke/thromboembolism and rehospitalization²⁰. Together, these findings suggest that milder multimorbidity clusters—typically involving fewer organ systems, lower systemic inflammation and greater physiological reserve—are more amenable to preventive interventions. Our results, showing the efficacy of the intervention in participants displaying an unspecific pattern of multimorbidity (often referred to as mild multimorbidity), confirm this hypothesis. In addition, psychiatric conditions, although disabling, often coexist with relatively preserved physical systems, allowing greater potential for improvement through lifestyle-based strategies. This potential is further enhanced when the intervention also improves mental health (for example, motivation, mood), which in turn promotes better adherence to the program^{21–23}. Consistent with this, a secondary analysis of the LIFE trial showed that, while depressive symptoms independently increased the risk of mobility disability, they did not modify intervention effects, indicating that older adults with depression benefit comparably from exercise in reducing disability risk²⁴. By contrast, multimorbidity profiles such as the cardiometabolic and respiratory patterns are characterized by greater systemic inflammation, vascular dysfunction and multisystem impairment^{25–28}, which may limit intervention responsiveness and increase susceptibility to iatrogenic effects or decompensation during follow-up^{16,29,30}.

Collectively, these studies and our own analysis indicate that, while multidomain interventions confer overall benefits in older adults with multimorbidity, their effectiveness is contingent upon disease architecture. This supports a precision approach to multimorbidity care, whereby stratifying individuals by patterns—both in experimental and clinical contexts—may enhance targeting, improve efficiency and ultimately reduce the burden of disability in aging populations.

This study has several limitations. First, as a post hoc analysis of a randomized clinical trial, it may have been underpowered to detect certain associations or interactions. As shown in our simulation analysis, larger samples could have strengthened statistical power and revealed subtler differences across multimorbidity patterns. Second, the identification of patterns was based on diagnostic information available within SPRINTT, which had limited coding granularity. Third, generalizability is constrained by the inclusion criteria of SPRINTT, which targeted older adults aged ≥ 70 years with physical frailty and sarcopenia, underscoring the need for replication in broader populations. Finally, although we hypothesized that multimorbidity patterns may reflect distinct biological substrates, this could not be tested due to a lack of biomarker data. Future studies integrating biological, functional and clinical measures are needed to validate and expand upon these findings.

In summary, the efficacy of a multicomponent intervention in preventing mobility disability differed across multimorbidity patterns. Participants with milder multimorbidity profiles, particularly those in the psychiatric and unspecific groups, derived the greatest benefit. These results suggest the value of multimorbidity-stratified strategies in tailoring preventive interventions for older adults. Future trials should incorporate multimorbidity profiling to refine targeting and maximize clinical impact.

Methods

Ethics

The SPRINTT study protocol was approved by the Ethics Committee of Università Cattolica del Sacro Cuore, Rome, Italy (protocol no. 15611/15), which served as the coordinating ethics committee for the trial. The protocol was subsequently ratified by the institutional ethics committees of all participating centers across the 11 European countries involved in the study. The trial was conducted in accordance with the ethical principles of the Declaration of Helsinki and the applicable national and international regulations governing clinical research. All participants provided written informed consent before enrollment and prior to the initiation of any study-related procedures.

Study design

This post hoc analysis is based on the SPRINTT randomized clinical trial, a multicenter study conducted across 11 European countries that evaluated whether a multicomponent program—including individualized physical activity, nutritional counseling and technology-assisted activity monitoring—could prevent mobility disability in older adults with frailty and sarcopenia^{9,31}. Full details of the study protocol are available at ClinicalTrials.gov ([NCT02582138](https://clinicaltrials.gov/ct2/show/study/NCT02582138)) and in a dedicated publication³².

Study population

Participants were community-dwelling adults aged ≥ 70 years with a newly conceptualized predisability condition termed physical frailty and sarcopenia³¹. The condition of interest was operationalized based on an SPPB score of 3–9 points combined with low appendicular lean mass according to the Foundation for the National Institutes of Health cutpoints³³, in the absence of mobility disability. Mobility disability was defined as the inability to complete a 400-m walk within 15 min without sitting, pausing for >1 min, requiring assistance or using walking aids other than a single straight cane (for example, tripods, walkers)³⁴. Individuals were excluded if they had conditions preventing active and safe participation in trial activities, such as self-reported mobility disability, cognitive impairment (a Mini-Mental State Examination (MMSE)³⁵ score of <24), terminal illness, current participation in structured exercise programs, medical contraindications as judged by study physicians or planned relocation outside the study area within the following 2 years. Eligible participants were randomly assigned (1:1) to either the multicomponent intervention group or the healthy aging lifestyle education group using a secure web-based randomization system with permuted blocks, stratified by study site, sex and baseline SPPB score (3–7 versus 8 or 9). Outcome assessors were blinded to treatment allocation, clinical and laboratory measurements, and intervention adherence.

For this analysis, we included randomized participants with baseline SPPB scores of 3–7 (the primary trial population) and with multimorbidity (defined as two or more chronic diseases). Because the analytical sample was inherited from the parent trial, no separate sample size calculation was performed. Recruitment occurred between January 2016 and November 2017; randomization began on February 3, 2016; and the last follow-up visit was on October 31, 2019. Details of screening, recruitment and baseline characteristics have been reported previously^{9,36}.

Intervention

Participants assigned to the multicomponent intervention received a program comprising structured physical activity, personalized nutritional counseling and technology-assisted support. The physical activity component included aerobic, resistance, flexibility and balance training, individually tailored and delivered through supervised center-based sessions (up to four times per week) and home exercises. Nutritional counseling focused on optimizing protein and energy intake, with supplementation provided when necessary³⁷. A thigh-worn actimeter was used to monitor adherence to physical activity, provide feedback and enhance motivation. The healthy aging

lifestyle education (control intervention) group attended monthly or twice-monthly educational sessions on healthy aging, each followed by simple stretching exercises. Both interventions were delivered for up to 36 months, depending on the enrollment date. Full details of the intervention procedures are reported elsewhere³².

Primary outcome

The primary outcome was incident mobility disability, assessed using the 400-m walk test^{34,38}. Participants were instructed to complete ten laps of a 20-m course at their usual pace, avoiding overexertion. The test was administered 3 months after randomization and then every 6 months from the baseline assessment. As specified in the main study⁹, when the test could not be performed, a predefined adjudication process was applied: mobility disability was assigned if gait speed over 4 m was $\leq 0.4 \text{ m s}^{-1}$, if gait speed was $> 0.4 \text{ m s}^{-1}$ with the use of a walking aid other than a single cane, or if walking disability was documented in medical records or reported by the participant or a proxy. Cases not meeting these criteria were reviewed by an independent adjudication committee using clinical data, functional assessments and adverse event reports. Adjudication was not an alternative definition of disability but a method to determine status when the 400-m test was unavailable, integrating observed and adjudicated outcomes to minimize missing endpoint data. Participants were censored at their last successful test if the criteria for disability were not met at trial end, at the first visit with a > 9 -month gap between two successful tests or at randomization if no postbaseline test was available. The 9-month threshold (prespecified) reflects the 6-month test schedule, with longer gaps indicating missed visits and uncertain timing. Therefore, participants were censored at the last reliable visit, with events occurring after gaps conservatively backdated. Potential informative censoring was partially addressed through adjudication and conservative handling procedures. Mobility disability was defined as occurring on the date a participant failed the 400-m walk test, was unable or unwilling to attempt it and was adjudicated as having the disability, was unable to attempt it without adjudication, or died.

Disease assessment

Chronic disease diagnoses were established through a standardized assessment integrating multiple data sources. Information was collected through physician-administered medical history interviews (including patient- or proxy-reported diagnoses); structured questionnaires (for example, MMSE, Center for Epidemiologic Studies Depression Scale³⁹); anthropometric measurements such as body mass index; vital signs such as blood pressure; and laboratory analyses (for example, fasting glucose, cholesterol, creatinine, hemoglobin). Medication inventories, coded using the Anatomical Therapeutic Chemical classification, were reviewed to support diagnostic adjudication when prescriptions clearly indicated a specific condition. Diagnoses were coded using the International Classification of Diseases, Ninth Revision, and aggregated into 60 chronic disease categories according to a validated, clinically driven classification system⁴⁰. Only baseline conditions were included in the analysis. Further details on disease assessment and coding are provided in Supplementary Table 1.

Covariates

Demographic variables, including age and sex, were collected during the prerandomization screening. Age was categorized into 5-year groups (that is, 70–74, 75–79, 80–84, 85–89 and ≥ 90 years). The number of chronic conditions for each participant was derived from the diagnoses classified using the methodology described above.

Statistics and reproducibility

Baseline characteristics of participants in the two intervention arms are reported as median (IQR) for continuous variables and as number (percentage) for categorical variables. Chronic conditions with a

prevalence of $\geq 2\%$ were used to identify homogeneous multimorbidity groups through LCA⁴¹. In this context, the term homogeneous indicates that individuals grouped within the same class tend to share similar combinations of chronic conditions. The optimal number of patterns was determined using the adjusted Bayesian information criterion and theoretical interpretability. Each pattern was labeled based on the distinctive set of chronic diseases that were disproportionately represented (that is, overexpressed) within that pattern. Chronic conditions were considered for pattern characterization and labeling if they were overexpressed in a given pattern. Overexpression was defined as an observed-to-expected ratio of ≥ 2 and an exclusivity of $\geq 25\%$. The observed-to-expected ratio was calculated by dividing the prevalence of a given disease within a specific pattern by its prevalence in the overall multimorbid population, while exclusivity was calculated by dividing the absolute frequency of that disease within the specific pattern by its frequency in the overall multimorbid population. Although each pattern is defined by a distinct combination of chronic conditions, it may also include additional conditions that are present but not prominently expressed. Each participant was assigned to the pattern with the highest posterior probability of membership⁴².

The primary endpoint (time to first occurrence of mobility disability or death) was compared across multimorbidity patterns and between intervention groups using two-sided log-rank tests at the 5% α -level, stratified by randomization factors of study site and sex.

To account for baseline differences between the intervention and control groups within each multimorbidity pattern, all subgroup analyses were conducted using IPTW. Propensity scores were estimated using generalized boosted models to flexibly model the treatment assignment mechanism and iteratively optimize covariate balance. In estimating the weights, we targeted the average treatment effect, ensuring that the weighted sample represents the entire study population rather than only the treated or untreated individuals. The boosting algorithm was guided by the ‘es.mean’ stopping rule, which selects the iteration that minimizes the mean absolute standardized difference across covariates. This configuration directs the algorithm to select the propensity score model that minimizes the mean standardized effect size across covariates, thereby improving balance without requiring a priori specification of nonlinearities or interactions. Covariate balance was evaluated within each multimorbidity pattern using the absolute standardized difference for all baseline variables before and after weighting.

Cox proportional hazards models, also stratified by site and sex, were used to estimate HRs with 95% CIs, additionally adjusting for multimorbidity patterns. Sandwich robust standard errors were used to account for the uncertainty introduced by the weighting procedure and to ensure valid inference under the IPTW framework. The proportional hazards assumption was assessed using Schoenfeld residuals by testing for independence between the residuals and time. Cumulative incidence functions were estimated using the Kaplan–Meier method.

To further characterize intervention effects, Royston–Parmar flexible parametric survival models were applied to estimate the event-free probability of the primary endpoint at 24 and 36 months, as well as the 36-month restricted mean time free from mobility disability or death, with corresponding 95% CIs. In these models, the log cumulative hazard was modeled as a natural cubic spline, with degrees of freedom selected according to the Bayesian information criterion. Subgroup analyses using Cox and flexible parametric models assessed whether intervention effects varied according to multimorbidity patterns.

To complement the frequentist analyses, we implemented a Bayesian partial pooling framework based on the Cox proportional hazards model¹⁹. For each simulation scenario, study-specific log HRs were modeled as hierarchical random effects drawn from a common population distribution. We assumed weakly informative priors for both the fixed effects and the between-study variance, allowing the amount of shrinkage to adapt to the information available in each study. Posterior

inference was obtained using Markov chain Monte Carlo sampling, and pooled treatment effects were estimated as the posterior means of the study-level parameters. In this Bayesian framework, 95% CrIs are obtained as quantiles of the posterior distribution of the parameters and represent the probability that the true subgroup-specific HRs lie within the interval, given the observed data and model. This approach formally accounts for heterogeneity while borrowing strength across studies, reducing instability in scenarios involving uneven subgroup distributions or small sample sizes. It was not possible to implement a Bayesian hierarchical (partial pooling) analog of the Royston–Parmar flexible parametric model comparable to the frequentist implementation. Therefore, results for the Royston–Parmar model are limited to frequentist analyses only.

We conducted an exploratory Monte Carlo simulation to provide contextual information on the statistical power to detect treatment-by-pattern interaction effects under the empirical conditions of the SPRINTT trial. The data-generating mechanism was based on the fitted Cox proportional hazards model: the empirical baseline cumulative hazard was extracted and inverted to simulate event times, and covariates were generated to match the observed multimorbidity pattern distribution and treatment allocation. In the primary simulated scenario, the data-generating mechanism incorporated the treatment-by-pattern interaction coefficients estimated in the trial; in a complementary scenario, these coefficients were set to zero to quantify the false-positive rate. For each scenario and for sample sizes ranging from $n = 1,199$ to 10,000, 1,000 datasets were generated, and Cox models were fitted to estimate power, false-negative probability and false-positive probability.

All analyses were conducted in R (version 4.5.2) using the following packages: *poLCA* to derive latent multimorbidity patterns, *twang* for generalized boosted models and propensity score weighting, *survival* for Cox proportional hazards models, *flexsurv* for Royston–Parmar flexible parametric models, *brms* for Bayesian hierarchical modeling and *ggplot* for graphics.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The SPRINTT trial data are not publicly available due to participant confidentiality and data protection requirements. Deidentified individual participant data underlying the results reported in this article may be requested from L. Mariotti (luca.mariotti1@unicatt.it). Requests will be reviewed to ensure compliance with participant confidentiality, ethical approvals and intellectual property requirements. A data-sharing agreement must be signed before the data are released.

Code availability

No custom code or mathematical algorithm was used in the study. Analysis scripts for this study are available from the corresponding author upon request.

References

1. Eurostat. Population structure and ageing. *Statistics Explained* https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Population_structure_and_ageing (2026).
2. World Health Organization. Decade of healthy ageing: plan of action. <https://www.who.int/publications/m/item/decade-of-healthy-ageing-plan-of-action> (2020).
3. Cesari, M. Role of gait speed in the assessment of older patients. *JAMA* **305**, 93–94 (2011).
4. Pantelaki, E., Maggi, E. & Crotti, D. Mobility impact and well-being in later life: a multidisciplinary systematic review. *Res. Transp. Econ.* **86**, 100975 (2021).
5. Hirvensalo, M., Rantanen, T. & Heikkinen, E. Mobility difficulties and physical activity as predictors of mortality and loss of independence in the community-living older population. *J. Am. Geriatr. Soc.* **48**, 493–498 (2000).
6. Rolland, Y. M. et al. Reliability of the 400-m usual-pace walk test as an assessment of mobility limitation in older adults. *J. Am. Geriatr. Soc.* **52**, 972–976 (2004).
7. Patrizio, E., Calvani, R., Marzetti, E. & Cesari, M. Physical functional assessment in older adults. *J. Frailty Aging* **10**, 141–149 (2021).
8. Pahor, M. et al. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. *JAMA* **311**, 2387–2396 (2014).
9. Bernabei, R. et al. Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project). *BMJ* **377**, e068788 (2022).
10. Skou, S. T. et al. Multimorbidity. *Nat. Rev. Dis. Primers* **8**, 48 (2022).
11. Vetrano, D. L. et al. Trajectories of functional decline in older adults with neuropsychiatric and cardiovascular multimorbidity: a Swedish cohort study. *PLoS Med.* **15**, e1002503 (2018).
12. Tazzeo, C. et al. Multimorbidity patterns and risk of frailty in older community-dwelling adults: a population-based cohort study. *Age Ageing* **50**, 2183–2191 (2021).
13. Damiano, C. et al. Frailty, multimorbidity patterns and mortality in institutionalized older adults in Italy. *Ageing Clin. Exp. Res.* **34**, 3123–3130 (2022).
14. Valletta, M. et al. Multimorbidity patterns and 18-year transitions from normal cognition to dementia and death: a population-based study. *J. Intern. Med.* **294**, 326–335 (2023).
15. Prados-Torres, A., Calderón-Larrañaga, A., Hancoco-Saavedra, J., Poblador-Plou, B. & van den Akker, M. Multimorbidity patterns: a systematic review. *J. Clin. Epidemiol.* **67**, 254–266 (2014).
16. Savikangas, T. et al. The impact of multimorbidity patterns on changes in physical activity and physical capacity among older adults participating in a year-long exercise intervention. *J. Aging Phys. Act.* **32**, 213–224 (2023).
17. Martínez-Velilla, N. et al. Specific multimorbidity patterns modify the impact of an exercise intervention in older hospitalized adults. *J. Multimorb. Comorb.* **12**, 26335565221145461 (2022).
18. Guralnik, J. M. et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. *J. Gerontol.* **49**, M85–M94 (1994).
19. Wang, Y. et al. Bayesian hierarchical models for subgroup analysis. *Pharm. Stat.* **23**, 1065–1083 (2024).
20. Corica, B. et al. Efficacy of the ABC pathway for integrated care across phenotypes of patients with atrial fibrillation: a latent-class analysis report from the mAFA-II clinical trial. *J. Gen. Intern. Med.* **40**, 1238–1247 (2025).
21. Dai, L., Zhou, H., Xu, X. & Zuo, Z. Brain structural and functional changes in patients with major depressive disorder: a literature review. *PeerJ* **7**, e8170 (2019).
22. Hird, E. J., Slanina-Davies, A., Lewis, G., Hamer, M. & Roiser, J. P. From movement to motivation: a proposed framework to understand the antidepressant effect of exercise. *Transl. Psychiatry* **14**, 273 (2024).
23. Noetel, M. et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. *BMJ* **384**, e075847 (2024).
24. Smail, E. J., Kaufmann, C. N., Anton, S. & Manini, T. M. Older adults with clinically relevant depressive symptoms have equal mobility benefit from a chronic physical activity intervention. *Ment. Health Phys. Act.* **25**, 100549 (2023).
25. Estrada, J. A. et al. Abnormal cardiovascular control during exercise: role of insulin resistance in the brain. *Auton. Neurosci.* **258**, 103239 (2025).

26. Malin, S. K. & Kirwan, J. P. Fasting hyperglycaemia blunts the reversal of impaired glucose tolerance after exercise training in obese older adults. *Diabetes Obes. Metab.* **14**, 835–841 (2012).
 27. Born, C. D. C. et al. Combined lifestyle interventions in the prevention and management of asthma and COPD: a systematic review. *Nutrients* **16**, 1515 (2024).
 28. Morgan, A. D., Zakeri, R. & Quint, J. K. Defining the relationship between COPD and CVD: what are the implications for clinical practice? *Ther. Adv. Respir. Dis.* **12**, 1753465817750524 (2018).
 29. Vetrano, D. L. et al. An international perspective on chronic multimorbidity: approaching the elephant in the room. *J. Gerontol. A Biol. Sci. Med. Sci.* **73**, 1350–1356 (2018).
 30. Gomes, P. F., Chacin-Suarez, A., Miller, S. A., Fischer, K. M. & Olson, T. P. Multimorbidity and peak oxygen uptake in patients undergoing cardiac rehabilitation. *JAMA Netw. Open* **8**, e2461331 (2025).
 31. Cesari, M. et al. Rationale for a preliminary operational definition of physical frailty and sarcopenia in the SPRINTT trial. *Aging Clin. Exp. Res.* **29**, 81–88 (2017).
 32. Landi, F. et al. The ‘Sarcopenia and Physical Frailty IN older people: multi-component Treatment strategies’ (SPRINTT) randomized controlled trial: design and methods. *Aging Clin. Exp. Res.* **29**, 89–100 (2017).
 33. McLean, R. R. et al. Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: the Foundation for the National Institutes of Health (FNIH) sarcopenia project. *J. Gerontol. A Biol. Sci. Med. Sci.* **69**, 576–583 (2014).
 34. Simonsick, E. M., Montgomery, P. S., Newman, A. B., Bauer, D. C. & Harris, T. Measuring fitness in healthy older adults: the health ABC long distance corridor walk. *J. Am. Geriatr. Soc.* **49**, 1544–1548 (2001).
 35. Folstein, M. F., Folstein, S. E. & McHugh, P. R. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. *J. Psychiatr. Res.* **12**, 189–198 (1975).
 36. Marzetti, E. et al. The ‘Sarcopenia and Physical Frailty IN older people: multi-component Treatment strategies’ (SPRINTT) randomized controlled trial: case finding, screening and characteristics of eligible participants. *Exp. Gerontol.* **113**, 48–57 (2018).
 37. Jyväkorpi, S. K. et al. The sarcopenia and physical frailty in older people: multi-component treatment strategies (SPRINTT) project: description and feasibility of a nutrition intervention in community-dwelling older Europeans. *Eur. Geriatr. Med.* **12**, 303–312 (2021).
 38. Fielding, R. A. et al. The Lifestyle Interventions and Independence for Elders Study: design and methods. *J. Gerontol. A Biol. Sci. Med. Sci.* **66**, 1226–1237 (2011).
 39. Radloff, L. S. The CES-D scale: a self-report depression scale for research in the general population. *Appl. Psychol. Meas.* **1**, 385–401 (1977).
 40. Calderón-Larrañaga, A. et al. Assessing and measuring chronic multimorbidity in the older population: a proposal for its operationalization. *J. Gerontol. A Biol. Sci. Med. Sci.* **72**, 1417–1423 (2017).
 41. Linzer, D. A. & Lewis, J. B. polCA: an R package for polytomous variable latent class analysis. *J. Stat. Softw.* **42**, 1–29 (2011).
 42. Marengoni, A. et al. Multimorbidity patterns and blood biomarkers of Alzheimer’s disease in community-dwelling cognitively unimpaired older adults. *Alzheimers Dement.* **21**, e70411 (2025).
- Boehringer Ingelheim International GmbH (Ingelheim am Rhein, Germany): Laurent Nicolas, Joachim Scholpp; Caretek S.r.l. (Turin, Italy): Gianluca Zia (coleader of the ICT Enabling Infrastructure and Operations work package), Cinzia Bertuzzi, Sabina De Giorgi, Luca Feletti, Alessandro Loria, Davide Mantovani, Elisa Marchioro, Francesco Mocci, Alberto Sacco, Maria Grazia Varesio; Centre Hospitalier Universitaire de Limoges (Limoges, France): Achille Tchalla (local principal investigator), Maxime Billot, Noëlle Cardinaud, Muriel Castelli, Marion Charenton-Blavignac, Cecilia Ciccolari-Micaldi, Thierry Dantoine, Caroline Gayot, Nicolas Giroult, Anael Larreur, Cécilie Laubarie-Mouret, Delphine Marchesseau, Thomas Mergans, Thai Binh Nguyen, Arnaud Papon, Johann Ribet, Isabelle Saulnier; Centre Hospitalier Universitaire de Toulouse (Toulouse, France): Bruno Vellas (local principal investigator and SPRINTT co-principal investigator for academia), Gabor Abellan Van Kan, Virginie Biville, Lauréane Brigitte, Matteo Cesari (academic coleader of the Clinical Consensus over Indication, Target Population and Clinical Trial Design for Data Generation work package), Carole Cervera, Céline Cluzan, Muriel Croizet, Sophie Dardenne, Marie Dorard, Charlotte Dupuy, Emilie Durand, Catherine Faisant, Sophie Guyonnet, Rémi Mauroux, Agathe Milhet, Sylvie Montel, Pierre-Jean Ousset, Cécile Picauron, Gaelle Soriano, Bernard Teyssere; Diabetes Frail Ltd. (Droitwich Spa, UK): Alan Sinclair (local principal investigator), Sital Harris, Allison Ogborne, Sarah Ritchie, Harriet Sinclair, Lois Tirrell, Caroline Sinclair; EU-Open S.r.l. (Veronella, Italy): Alfredo Cesario (coleader of the Regulatory Consensus work package), Barbara Cabin, Pim de Boer, Claire Ignaszewski, Ingrid Klingmann; Friedrich-Alexander-Universität Erlangen-Nürnberg (Nuremberg, Germany): Cornel C. Sieber (local principal investigator), Tina Auerswald, Christof Engel, Anna Franke, Ellen Freiburger, Ulrike Freiheit, Susann Gotthardt, Karin Kampe, Robert Kob, Christine Kokott, Carolin Kraska, Christian Meyer, Veronika Reith, Hanna Rempe, Daniel Schoene, Gabrielle Sieber, Kerstin Zielinski; University of Göttingen Medical Center (Göttingen, Germany): Stefan D. Anker (academic leader of the Biomarkers Qualification work package), Nicole Ebner, Stephan von Haehling; GlaxoSmithKline Research and Development Ltd. (Brentford, UK): Michael Benecky; Hospital Universitario de Getafe (Getafe, Spain): Leocadio Rodriguez-Mañas (local principal investigator), Alejandro Alvarez-Bustos, Cristina Alonso Bouzon, Beatriz Contreras Escamez, Jimmy Gonzales Turin, Olga Laosa Zafra, Myriel Lopez Tatis, Laura Pedraza Sepulveda, Juan Luis Sanchez, Carlos Sanchez Puellas; Hospital Universitario Ramón y Cajal, IRYCIS (Madrid, Spain): Alfonso J. Cruz-Jentoft (local principal investigator and academic coleader of the Clinical Study Implementation and Operations work package), Juan Álvarez-Santos, Belén Fernández-Jiménez, Jesús Mateos-del Nozal, Beatriz Montero-Erasquin, Beatriz Ponce-Moreno, Cristina Roldán-Plaza, Alfonso Romera-de Vicente, Vicente Sánchez-Cadenas, Carmen Sánchez-Castellano, Elisabet Sánchez-García, María Nieves Vaquero-Pinto; INSERM/Université Toulouse III—Paul Sabatier UMR1027 (Toulouse, France): Sandrine Andrieu, Alessandro Blasimme, Cedric Dray, Emmanuelle Rial-Sebbag, Philippe Valet; Institut de Recherches Internationales Servier IRIS (Suresnes, France): Gorostiaga Ayestarán (EFPIA coleader of the Clinical Study Implementation and Operations work package), Laurence Laigle, Itziar Martinez-Melchor, Belen Surroca; IRCCS INRCA (Ancona, Italy): Fabrizia Lattanzio (local principal investigator), Stefania Ambrosi, Renato Baldoni, Serena Bernabei, Anna Rita Bonfigli, Silvia Bustacchini, Barbara Carrieri, Antonio Cherubini (leader of the Stakeholder Information and Results Dissemination work package), Anna Rita Costantini, Michela Cucchi, Giuseppina Dell’Aquila, Emma Espinosa, Luciano Izzo, Massimiliano Fedecostante, Michela Mannoni, Antonella Mengarelli, Marino Modestino, Emanuele Monterubbianesi, Stefano Piomboni, Antonia Scrimieri, Eddy Severini, Fabiana Mirella Trotta, Lorella Vece, Susanna Venere, Elisa Zengarini; Landspítali—The National University Hospital of Iceland (Reykjavík, Iceland): Pálmi V. Jónsson (local principal

Acknowledgements

SPRINTT consortium partners—Astellas Pharma Europe BV (Leiden, Netherlands): Andeleeb Dahy, Makoto Kashiwa; BlueCompanion Ltd. (London, UK): Susanna Del Signore;

investigator), Milan Chang, Hrafnhildur Eymundsdóttir, Ólóf Guðný Geirsdóttir, Steinn Baugur Gunnarsson, Steinunn Guðnadóttir, Alfons Ramel, Konstantín Shcherbak; Medizinische Universität Graz (Graz, Austria): Regina Roller-Wirnsberger (local principal investigator), Gerhard Wirnsberger; Novartis Pharma AG (Basel, Switzerland): Ronenn Roubenoff (scientific coordinator of SPRINTT and EFPIA coleader of the Clinical Consensus over Indication, Target Population and Clinical Trial Design for Data Generation work package), Sheena Kao, Ram R. Miller (EFPIA coleader of the Biomarkers Qualification work package), Romain Barnouin; Roessingh Research and Development BV (Enschede, Netherlands): Lex van Velsen Miriam Vollenbroek-Hutten; Sanofi-Aventis Recherche & Développement (Chilly-Mazarin, France): Philippe Bordes (project coordinator and EFPIA coleader of the Project Management and Oversight work package), Christian Asbrand, Raphael Bejuit (EFPIA coleader of the Evaluation of Results work package), Sandrine Durand, Florence Joly (EFPIA coleader of the Health Technology Assessment work package), Klaus Flechsenhar, Harmonie Goyeau, Régis Le Lain (EFPIA coleader of the Regulatory Consensus work package), Jerome Mshihid, Aurèle Ndja (EFPIA coleader of the ICT Enabling Infrastructure and Operations work package); Silesian Hospital in Opava (Opava, Czech Republic): Ingrid Rýznarová (local principal investigator), Ivana Drastichova, Eva Hasalíková, Radim Hucko, Seget Jakub, Monika Janáčová, Michaela Kilmková, Martina Parízková, Kristyna Pavelková, Michaela Redrova, Petra Rusková; Università Cattolica del Sacro Cuore (Rome, Italy): Roberto Bernabei (SPRINTT principal investigator for academia), Francesco Landi (local principal investigator and academic coleader of the Clinical Study Implementation and Operations work package), Michele Basile, Damiano Biscotti, Claudio Boni, Vincenzo Brandi, Marianna Broccatelli, Riccardo Calvani, Carilia Celesti, Americo Cicchetti (academic coleader of the Health Technology Assessment work package), Hélio Jose Coelho-Junior, Agnese Collamati, Silvia Coretti, Emanuela D'Angelo, Mariaelena D'Elia, Eugenio Di Brino, Giovanni Landi, Luca Mariotti (project manager and academic coleader of the Project Management and Oversight work package), Anna Maria Martone, Emanuele Marzetti (academic coleader of the Evaluation of Results work package), Elena Ortolani, Teodosio Pafundi, Cecilia Pantanelli, Anna Picca, Matteo Ruggeri, Filippo Rumi, Sara Salini, Giulia Saveria, Elisabetta Serafini, Matteo Tosato, Davide L. Vetrano, Fabio Vitale; Università degli Studi di Firenze (Florence, Italy): Mauro Di Bari (academic coleader of the Evaluation of Results work package); Università degli Studi di Parma (Parma, Italy): Marcello Maggio (local principal investigator), Elisa Adorni, Fulvio Lauretani, Yari Longobucco, Giovanna Maria Pelà, Sara Tagliaferri; Université de Paris (Paris, France): Thomas Rapp (academic coleader of the Health Technology Assessment work package), Yves Arrghi, Bastian Ravestein, Jérôme Ronchetti, Quittterie Roquebert, Jonathan Sicsic, Nicolas Sirven; Universiteit Maastricht (Maastricht, Netherlands): Annemie M.W.J. Schols (local principal investigator), Harry Gosker, Jos M.G.A. Schols, Lisanne Schuurman, Nick Smeets, Coby van de Bool, Claire Weling; University of Helsinki and Helsinki University Hospital (Helsinki, Finland): Timo Strandberg (local principal investigator), Katja Hallikas, Marjatta Herranen, Laura Hyvönen, Kirsi Ikonen, Satu Jyväkorpi, Anne Karppi-Sjöblom, Kaisa Karvinen, Tarja Kindstedt, Saana Leirimaa, Hanna Öhman, Kaisu Pitkälä, Anja Punkka, Anna-Maria Saavalainen, Tuulia Salo, Katja Sohlberg, Reijo Tilvis, Annele Urtamo, Hannu Vanhanen; Univerzita Karlova v Praze (Prague, Czech Republic): Eva Topinková (local principal investigator), Lucie Bautzská, Tereza Gueye, Ilona Jukličková, Pavla Mádlová, Helena Mejstříková, Helena Michálková, Eva Klára Novotná, Tereza Vágnerová; Uniwersytet Jagielloński Collegium Medicum (Krakow, Poland): Anna Skalska (local principal investigator), Ewa Blaszczyk-Bebenek, Marcin Cwynar, Joanna Czesak, Paulina Fatyga, Malgorzata Fedyk-Lukasik, Tomasz Grodzicki, Paulina Jamrozik, Zbigniew Janusz, Ewa Klimek, Sylwia Komoniewska, Maria Kret, Maciej Ozog, Agnieszka Parnicka, Katarzyna

Petitjean, Anna Pietrzyk, Karolina Piotrowicz, Barbara Skalska-Dulinska, Damian Starzyk, Katarzyna Szczerbinska, Borys Witkiewicz, Anna Włodarczyk, Wiesława Zgud.

Author contributions

D.L.V. and R.C. conceptualized the study. D.L.V., R.C., E.M., C.G. and F.T. designed the study. A.C., M.T., S.v.H., E.M., L.S. and F.L. were involved in data acquisition. C.G. and F.T. performed the statistical analyses. D.L.V. and R.C. wrote the first draft. All authors edited, reviewed and approved the final version of the paper. R.C. and E.M. are the guarantors of this work and, as such, have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding

This work was funded by a grant from the Innovative Medicines Initiative Joint Undertaking (IMI-JU 115621), which included in-kind support from member companies of the European Federation of Pharmaceutical Industries and Associations (Sanofi-Aventis, Novartis, GlaxoSmithKline, Servier, Astellas Pharma and Boehringer Ingelheim). D.L.V. was supported by the Swedish Research Council (project number 2021-03324), the Karolinska Institutet Strategic Research Area in Epidemiology and Biostatistics (SFOepi) in 2021 and 2023, and the Karolinska Institutet Strategic Research Area in Neuroscience in 2025. E.M. received support from the European Union's Next Generation EU PRIN (2022YNENP3). The authors also received cofunding from Next Generation EU in the context of the National Recovery and Resilience Plan, Investment PE8—Project Age-It: 'Ageing Well in an Ageing Society'. This resource was cofinanced by Next Generation EU (DM 1557 11.10.2022). The views and opinions expressed are solely those of the authors and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the European Commission can be held responsible for them. The funders had no role in the study design, data collection, data analysis, data interpretation, writing of the report or the decision to submit the article for publication. Open access funding provided by Università Cattolica del Sacro Cuore within the CRUI-CARE Agreement.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s43587-026-01188-x>.

Correspondence and requests for materials should be addressed to Emanuele Marzetti.

Peer review information *Nature Aging* thanks the anonymous reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate

if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted

use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2026

Davide Liborio Vetrano^{1,2}, **Caterina Gregorio**¹, **Federico Triolo**¹, **Luca Soraci**³, **Antonio Cherubini**^{4,5}, **Matteo Tosato**^{6,7}, **Stephan von Haehling**^{8,9}, **Emanuele Marzetti**^{6,7}✉, **Francesco Landi**^{6,7,10} & **Riccardo Calvani**^{6,7,10}

¹Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.

²Stockholm Gerontology Research Center, Stockholm, Sweden. ³Unit of Geriatric Medicine and Clinical Epidemiology, Italian National Institute of Health and Sciences on Ageing (INRCA IRCCS), Cosenza, Italy. ⁴Geriatrics, Accettazione Geriatrica e Centro di Ricerca per l'Invecchiamento, INRCA IRCCS, Ancona, Italy. ⁵Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica delle Marche, Ancona, Italy. ⁶Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy. ⁷Department of Geriatrics, Orthopaedics and Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy. ⁸Department of Cardiology and Pneumology, University Medical Centre Göttingen, Georg-August University, Göttingen, Germany.

⁹German Centre for Cardiovascular Research (DZHK), Partner Site Göttingen, Göttingen, Germany. ¹⁰These authors contributed equally: Francesco Landi, Riccardo Calvani. ✉e-mail: emanuele.marzetti@unicatt.it

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a	Confirmed
☐	☒ The exact sample size (<i>n</i>) for each experimental group/condition, given as a discrete number and unit of measurement
☐	☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
☐	☒ The statistical test(s) used AND whether they are one- or two-sided <i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>
☐	☒ A description of all covariates tested
☐	☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
☐	☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
☐	☒ For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
☐	☒ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
☒	☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
☒	☐ Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	All data were collected through a CleanWEB-based software compliant with international GCP and cGMP standards
Data analysis	All analyses were conducted in R (version 4.5.2)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Anonymised raw trial data can be shared on request to Luca Mariotti (luca.mariotti1@unicatt.it). A data access agreement needs to be signed

Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

Reporting on sex and gender	Information on sex was collected in the SPRINTT dataset. Gender information was not collected. Analyses were stratified by sex with results reported in tables and figures.
Reporting on race, ethnicity, or other socially relevant groupings	Information on race and ethnicity, living arrangement, marital status, income, and education attainment was collected in the SPRINTT dataset but was not used in the present study.
Population characteristics	Demographic variables, including age and sex, were collected during the pre-randomisation screening. Median age was 79.0 yrs (IQR: 75.0-84.0), and 71% were women. The number of chronic conditions for each participant was derived from diagnoses classified using a standardised assessment integrating multiple data sources (e.g., medical history interviews, structured questionnaires, anthropometric measurements, vital signs, and laboratory analyses). The median number of chronic conditions was 6.0 (IQR: 5.0-8.0). Baseline characteristics were comparable between intervention groups. Diagnoses were coded according to the International Classification of Diseases, Ninth Revision (ICD-9), and aggregated into 60 chronic disease categories using a validated classification system. Medications were collected and reviewed to support diagnostic adjudication.
Recruitment	Each study site developed their own recruitment plan to suit local conditions. Common strategies included media ads, direct mail, community outreach, and engagement with healthcare providers and senior organizations. Promotional materials were widely distributed, and a dedicated website (www.mysprintt.eu) supported awareness of the project among the general public. A centralised monitoring team tracked recruitment outcomes, shared effective strategies, and supported sites with difficulties through teleconferences, visits, and tailored corrective actions.
Ethics oversight	The study protocol was approved by the Ethics Committee of the Università Cattolica del Sacro Cuore, Rome, Italy (approval no. 15611/15), and subsequently ratified by the ethics committees of all participating institutions. Participation was voluntary, and no financial compensation was provided. Written informed consent was obtained from all participants at screening.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Calculation of sample size for the SPRINTT trial was based on the LIFE study (NCT01072500), which showed that physical activity reduced mobility disability in participants with SPPB < 8, the trial aimed to enroll 1,200 participants with SPPB 3–7. This provided 85% power to detect a 25% reduction in mobility disability risk over 36 months (assuming 434 events, 25% dropout over two years, and a two-sided $\alpha = 0.05$). An exploratory cohort of 300 participants with SPPB 8–9 was added to broaden the functional spectrum, its size determined by feasibility and resources. For the present analysis, only randomised participants with baseline SPPB 3–7 and multimorbidity (≥ 2 chronic conditions) were included. No formal sample size estimation was performed for this study.
Data exclusions	A total of six participants were excluded from the analysis, as they exhibited fewer than two comorbid conditions, not fulfilling the clinical criterion for multimorbidity adopted in our analyses.
Replication	Study results were not replicated in independent cohorts. Data are available from the corresponding author upon reasonable request for replication by qualified researchers.
Randomization	Participants were randomised in a 1:1 ratio to either the multicomponent intervention or the lifestyle education control group, using a web-based randomisation system implementing a permuted block algorithm. Randomisation was stratified by study site, and site.
Blinding	An evaluator-blinded design was used to preserve trial integrity. Outcome assessors were unaware of group allocation, clinic and laboratory results, and participant adherence to the assigned intervention.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
☒	☐ Antibodies
☒	☐ Eukaryotic cell lines
☒	☐ Palaeontology and archaeology
☒	☐ Animals and other organisms
☐	☒ Clinical data
☒	☐ Dual use research of concern
☒	☐ Plants

Methods

n/a	Involved in the study
☒	☐ ChIP-seq
☒	☐ Flow cytometry
☒	☐ MRI-based neuroimaging

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	ClinicalTrials.gov NCT02582138
Study protocol	The full study protocol is accessible at https://www.bmj.com/content/bmj/suppl/2022/05/11/bmj-2021-068788.DC1/berr068788.www.pdf
Data collection	Data were collected at study centres. Recruitment took place between January 2016 and November 2017, and the last follow-up visit was conducted on 31 October 2019.
Outcomes	The primary outcome was incident mobility disability, assessed using the 400 m walk test. Participants were instructed to complete ten laps of a 20 m course at their usual pace, avoiding overexertion. The test was administered three months after randomisation and every six months thereafter. When the test could not be performed, a predefined adjudication process was applied. Mobility disability was assigned if gait speed over 4 m was equal or below 0.4 m/s, or >0.4 m/s with the use of a walking aid other than a single cane, or based on medical records and self- or proxy-reported walking disability. Cases not meeting these criteria were reviewed by an independent adjudication committee, which evaluated clinical data, functional assessments, and adverse event reports. Participants were censored at their last successful test if disability criteria were not met at the end of the trial, at the first visit with a gap >9 months between two successful tests, or at randomisation if no post-baseline test was available. Mobility disability was defined as occurring on the date when a participant failed the 400 m walk test, was unable or unwilling to attempt it, and adjudicated as disabled, was unable to attempt without adjudication, or died.

Plants

Seed stocks	<i>Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.</i>
Novel plant genotypes	<i>Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.</i>
Authentication	<i>Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosaicism, off-target gene editing) were examined.</i>